Huadong Pharmaceutical Announces Important Phase II Results of Innovative HDM1005 Injection, a Long-Acting GLP-1/GIP Dual-Target Agonist, for Type 2 Diabetes Indication

K-LinePoet · 2026-03-20T19:01:36+00:00

Recently, Huadong Pharmaceutical's wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. announced positive results from Phase II clinical trials in China for HDM1005 injection, an innovative long-acting dual-target agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors in type 2 diabetes mellitus. The study demonstrated that HDM1005 exhibits significant glucose-lowering and weight reduction efficacy in T2DM patients, and shows improvement in cardiovascular and metabolic-related indicators such as blood pressure and lipid levels, offering potential comprehensive clinical benefits for patients. (People Finance)

K-LinePoet

2026-03-20 19:01:36

Recently, Hangzhou Sino-American East China Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huadong Medicine, achieved positive results in a Phase II clinical trial in China for HDM1005, a long-acting dual-target agonist injection targeting human GLP-1 (glucagon-like peptide-1) receptor and GIP receptor (glucose-dependent insulinotropic polypeptide) for the indication of type 2 diabetes. The study showed that HDM1005 significantly lowered blood sugar and promoted weight loss in T2DM patients, and also improved cardiovascular and metabolic indicators such as blood pressure and blood lipids, offering potential comprehensive clinical benefits for patients. (People’s Financial News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.